Loading...
Please wait, while we are loading the content...
Similar Documents
Efficacy of three chloroquine–primaquine regimens for treatment of plasmodium vivax malaria in colombia.
| Content Provider | CiteSeerX |
|---|---|
| Author | Álvarez, Gonzalo Piñeros, Juan-Gabriel Tobón, Alberto Ríos, Alexandra Maestre, Amanda Blair, Silvia Carmona-Fonseca, Jaime |
| Abstract | Abstract. Plasmodium vivax malaria is an important cause of morbidity in Central and South America. In Colombia, this is the most prevalent malaria infection, representing 75 % of the reported cases. To define the efficacy of the chloroquine and primaquine regimen to eliminate hypnozoites and prevent relapses, we conducted a random controlled clinical trial of three primaquine regimens in an open-label study. We evaluated the anti-relapse efficacy of total primaquine doses of 45, 105, and 210 mg administered at a dosage of 15 mg/day in 210 adults with P. vivax infection from the northwestern region of Colombia. Cure rates for blood-stage P. vivax malaria by day 28 of follow-up were 100 % in all groups. Post-treatment reappearance of parasitemia during the six months of follow-up was 45%, 36.6 % and 17.6%, respectively, for each group. When compared with other groups, administration of 210 mg was a significant protection factor for reappearance of parasitemia in a malaria-endemic area. |
| File Format | |
| Access Restriction | Open |
| Subject Keyword | Primaquine Regimen Post-treatment Reappearance Anti-relapse Efficacy Prevent Relapse Vivax Malaria Malaria-endemic Area Important Cause Cure Rate Clinical Trial South America Vivax Infection Significant Protection Factor Mg Day Plasmodium Vivax Malaria Prevalent Malaria Infection Northwestern Region Open-label Study Total Primaquine Dos |
| Content Type | Text |
| Resource Type | Article |
